HIV drug dosing study aims to protect moms and babies

NCT ID NCT05630638

Recruiting now Disease control Sponsor: University of Liverpool Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the HIV drug doravirine works in pregnant women. Researchers want to find the right dose to keep the virus under control and protect the baby. About 76 pregnant women with HIV will take either doravirine or standard HIV medication starting in the second trimester. The study will measure drug levels in the blood, breastmilk, and cord blood to ensure safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Doravirine (with lamivudine and tenofovir disoproxil)
What this could lead to: If successful, this could help establish safe and effective doravirine dosing for pregnant women with HIV, improving treatment options during pregnancy.
What could go wrong: This is a small, early-phase pharmacokinetic study, not designed to prove long-term outcomes. Results may not apply to all populations, and there are unknown risks to the baby.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Show contact details

Locations

Desmond Tutu Health Foundation
RECRUITING

Cape Town, South Africa

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.